Showing results (161-170 of 195) with videos related to
Sort By:
Pageof 20
The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.Cancer Cell|May 6, 2014
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expressionChunxiao Xu, Christine M Fillmore, Shohei Koyama, et al.Cancer Discovery|April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.Therapeutic Advances in Medical Oncology|August 2, 2024
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinibYongfeng Yu, Wen Dong, Yanxia Shi, et al.Translational Lung Cancer Research|October 24, 2025
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with <i>MET</i> exon 14 skipping mutated non-small cell lung cancerShun Lu, Yongfeng Yu, Jianya Zhou, et al.Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.BMC Medicine|February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Jianhua Chen, Helong Zhang, et al.Cancer Communications (London, England)|May 29, 2025
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trialYing Cheng, Shuang Zhang, Liang Han, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2023
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 TrialJianchun Duan, Lin Wu, Kunyu Yang, et al.Pageof 20